Completion of the study enables Fero Industries to move forward with plans for registration, licensing and distribution of Sucanon across the Middle East.
The pre-clinical and clinical studies demostrated that Sucanon and other insulin sensitizers help in lowering patient’s blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin.
Sucanon has been approved for prescription sale in China and Peru.
It is also approved as an OTC treatment for type-2 diabetes by regulatory authorities in Mexico, and is distributed there under an exclusive agreement with Merck.
Fero chief operating officer Luis Lopez said the results of the University of Tehran human clinical trials have confirmed the safety and effectiveness of Sucanon as a treatment for type-2 diabetes and pre-diabetes across the entire spectrum of the Middle Eastern population.
"With this study in hand, the company has begun the process of negotiating licensing agreements with established pharmaceutical distributors and is preparing registration dossiers to be submitted to the Ministries of Health in several countries across the Middle East region, including Iran, Kuwait, Jordan, Saudi Arabia, Palestine, Qatar and Egypt," Lopez said.